Figure 3 | Modern Pathology

Figure 3

From: Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients

Figure 3

Kaplan–Meier analysis of prostate-specific antigen (PSA) progression-free, castration-resistant prostate cancer (CRPC) progression- free, cancer-specific, and overall survival according to AR-V7 status in all enrolled patients (a–d) and in the patients with metastases (e–h). (a) The median PSA progression-free survival in AR-V7-positive patients was 13 months (95% CI: 6.956–18.044), whereas in AR-V7-negative patients it was 38 months (95% CI: 32.685–42.315), the hazard ratio for PSA progression with AR-V7 positivity was 5.435; 95% CI (3.374–8.754; P<0.0001 by the log-rank test). (b) The median time to castration-resistant prostate cancer progression in AR-V7-positive patients was 12 months (95% CI: 8.562–15.438), whereas in AR-V7-negative patients it was 38 months (95% CI: 31.141–42.859), the hazard ratio for castration-resistant prostate cancer progression with AR-V7 positivity was 5.571 (95% CI: 3.445–9.007; P<0.0001 by the log-rank test). (c) The median cancer-specific survival time in AR-V7-positive patients was 32 months (95% CI: 19.879–44.121), whereas in AR-V7-negative patients it was 125 months (95% CI: 24.426–224.574), the hazard ratio for cancer-specific survival with AR-V7 positivity was 5.068 (95% CI: 2.556–10.049; P<0.0001 by the log-rank test). (d) The median overall survival time in AR-V7-positive patients was 32 months (95% CI: 19.879–44.121), whereas in AR-V7-negative patients it was 125 months (95% CI: 35.300–213.700), the hazard ratio for overall survival with AR-V7 positivity was 4.667 (95% CI: 2.382–9.142; P<0.0001 by the log-rank test). (e) The median PSA progression-free survival in AR-V7-positive patients with metastases was 12 months (95% CI: 8.002–15.998), whereas in AR-V7-negative patients it was 34 months (95% CI: 26.244–41.756), the hazard ratio for PSA progression with AR-V7 positivity in patients with metastases was 5.879 (95% CI: 3.480–9.931; P<0.0001 by the log-rank test). (f) The median time to castration-resistant prostate cancer progression in AR-V7-positive patients with metastases was 12 months (95% CI: 9.569–14.431), whereas in AR-V7-negative patients it was 34 months (95% CI: 26.855–41.145), the hazard ratio for castration-resistant prostate cancer progression with AR-V7 positivity in patients with metastases was 5.899 (95% CI: 3.476–10.012; P<0.0001 by the log-rank test). (g) The median cancer-specific survival time in AR-V7-positive patients with metastases was 26 months (95% CI: 9.196–42.804) whereas in AR-V7-negative patients it was 125 months (95% CI: 24.166–224.834), the hazard ratio for cancer-specific survival with AR-V7 positivity patients with metastases was 6.122 (95% CI: 2.847–13.164; P<0.0001 by the log-rank test). (h) The median overall survival time in AR-V7-positive patients with metastases was 26 months (95% CI: 9.196–42.804), whereas in AR-V7-negative patients it was 125 months (95% CI: 34.957–214.043), the hazard ratio for overall survival with AR-V7 positivity patients with metastases was 6.122 (95% CI: 2.847–13.164; P<0.0001 by the log-rank test).

Back to article page